Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GUILLERMO VALENZUELA

NPI
1245252402
CMS profile
101277
Location
PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$185,529.14

288 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GUILLERMO VALENZUELA

NPI 1245252402 · CMS profile ID 101277

PLANTATION, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GUILLERMO VALENZUELA, NPI 1245252402, CMS profile ID 101277, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1245252402?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

288 matching records · $185,529.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 288 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 288.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Solta Medical, a division of Bausch Health US, LLC $24.6108/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206128511 CMS
Alvogen Inc $23.1108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1209953036 CMS
GlaxoSmithKline, LLC. $650.0008/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190400774 CMS
GlaxoSmithKline, LLC. $650.0008/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1191720333 CMS
Mallinckrodt Hospital Products Inc. $21.5608/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212005293 CMS
SOBI, INC $114.9208/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240239421 CMS
GlaxoSmithKline, LLC. $25.7408/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190895986 CMS
Amgen Inc. $25.4008/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228354944 CMS
GENZYME CORPORATION $10.9808/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233300138 CMS
GENZYME CORPORATION $31.1608/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233300140 CMS
GENZYME CORPORATION $7,632.0008/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1233300314 CMS
GENZYME CORPORATION $389.8308/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233300316 CMS
GENZYME CORPORATION $680.1708/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233300318 CMS
GENZYME CORPORATION $249.8808/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1233300320 CMS
GENZYME CORPORATION $142.2808/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233300258 CMS
ABBVIE INC. $13.2508/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611742 CMS
GENZYME CORPORATION $6.1108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233300302 CMS
Amgen Inc. $4.6008/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227095639 CMS
Amgen Inc. $6.0408/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227095643 CMS
ANI Pharmaceuticals, Inc. $24.7508/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248613281 CMS
UCB, Inc. $6,000.0007/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224353120 CMS
ABBVIE INC. $33.9107/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611735 CMS
ABBVIE INC. $41.4207/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204611739 CMS
GlaxoSmithKline, LLC. $30.4607/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191762464 CMS
Novartis Pharmaceuticals Corporation $24.9807/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200384814 CMS
ABBVIE INC. $229.8207/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204611731 CMS
E.R. Squibb & Sons, L.L.C. $2.8707/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184918534 CMS
Radius Health, Inc. $31.3607/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249509994 CMS
AstraZeneca Pharmaceuticals LP $26.1907/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214804630 CMS
GlaxoSmithKline, LLC. $1,300.0007/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1190519390 CMS
Janssen Biotech, Inc. $5,075.0007/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175222651 CMS
Janssen Biotech, Inc. $5.4907/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175223235 CMS
Janssen Biotech, Inc. $42.7507/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1175223921 CMS
UCB, Inc. $18.1107/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224353118 CMS
Amgen Inc. $6.8107/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227095647 CMS
AstraZeneca Pharmaceuticals LP $5.3407/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1215340722 CMS
UCB, Inc. $125.0007/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224353114 CMS
UCB, Inc. $1,317.9307/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224353116 CMS
GENZYME CORPORATION $23.1207/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233300254 CMS
ABBVIE INC. $17.7707/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204611727 CMS
UCB, Inc. $15.0007/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1224353112 CMS
ABBVIE INC. $175.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204611716 CMS
ABBVIE INC. $775.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204611719 CMS
ABBVIE INC. $3,600.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1204611723 CMS
IDORSIA PHARMACEUTICALS US INC $5,000.0007/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1243416780 CMS
Janssen Biotech, Inc. $1,450.0006/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1175223254 CMS
UCB, Inc. $1,775.0006/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1224353110 CMS
ABBVIE INC. $570.4006/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204611707 CMS
ABBVIE INC. $724.7206/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1204611712 CMS
GENZYME CORPORATION $148.1206/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233300272 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $317,814.12 563
PY2020 $171,096.58 326
PY2021 $163,958.56 323
PY2022 $176,887.78 377
PY2023 $247,786.44 369
PY2024 $214,820.16 299
PY2025 $185,529.14 288

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,099,441.21 158
PY2024 Recipient $6,385.02 1
PY2024 Principal investigator $2,370,149.15 81
PY2023 Recipient $2,369.50 1
PY2023 Principal investigator $1,705,553.77 58
PY2022 Recipient $1,219.06 3
PY2022 Principal investigator $2,396,921.97 53
PY2021 Recipient $1,791.00 2
PY2021 Principal investigator $1,602,769.13 98
PY2020 Recipient $14,554.37 6
PY2020 Principal investigator $1,165,555.50 146
PY2019 Recipient $75,629.31 3
PY2019 Principal investigator $1,346,131.53 128

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,913.22 12/25/2025 Non-covered Recipient Entity
IRIS Research and Development LLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228817022
Principal investigator 1 Janssen Research & Development, LLC $2,028.00 12/22/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411698
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,698.59 12/19/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223290026
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,272.70 12/17/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289902
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,405.52 12/16/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190309362
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 12/15/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411589
Principal investigator 1 Janssen Research & Development, LLC $4,970.00 12/15/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411628
Principal investigator 1 ABBVIE INC. $8,940.00 12/04/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202526894
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 12/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667166
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 12/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667168
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667170
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.00 12/01/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190301437
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,040.99 12/01/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289138
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,090.70 11/13/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220792001
Principal investigator 1 Janssen Research & Development, LLC $31,948.00 11/10/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411729
Principal investigator 1 ABBVIE INC. $68.75 11/04/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202520695
Principal investigator 1 ABBVIE INC. $18,710.00 11/04/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520697
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 11/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667160
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 11/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667162
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667164
Principal investigator 1 Janssen Research & Development, LLC $2,875.00 10/31/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411563
Principal investigator 1 SANOFI US SERVICES INC. $3,625.00 10/27/2025 Non-covered Recipient Entity
Iris Research And Development LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226128107
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 10/20/2025 Non-covered Recipient Entity
Iris Research And Development LLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,562.72 10/17/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223287139
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,283.14 10/15/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287009
Principal investigator 1 ABBVIE INC. $1,908.58 10/09/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202515593
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,344.40 10/06/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791999
Principal investigator 1 Janssen Research & Development, LLC $3,866.00 10/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411546
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 10/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411674
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667154
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 10/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667156
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 10/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667158
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,575.99 10/01/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190301447
Principal investigator 1 Amgen Inc. $39,197.88 09/26/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246642995
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 09/24/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667146
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 09/24/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667148
Principal investigator 1 Boehringer Ingelheim International GmbH $5.16 09/24/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667150
Principal investigator 1 Boehringer Ingelheim International GmbH $1.28 09/24/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667152
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 09/22/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,542.40 09/17/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285590
Principal investigator 1 ARGENX US, INC. $3,500.00 09/12/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis No dispute reported 06/30/2026 1237151245
Principal investigator 1 ARGENX US, INC. $26,212.00 09/12/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis No dispute reported 06/30/2026 1237151248
Principal investigator 1 Amgen Inc. $53,042.10 09/10/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246642985
Principal investigator 1 SANOFI US SERVICES INC. $6,000.00 09/03/2025 Non-covered Recipient Entity
Iris Research And Development LLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128098
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667130
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 09/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667132
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 09/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667134
Principal investigator 1 Janssen Research & Development, LLC $5,038.00 09/01/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411582
Principal investigator 1 Janssen Research & Development, LLC $2,389.00 08/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411574
Principal investigator 1 Janssen Research & Development, LLC $2,750.00 08/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411621
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,928.20 08/22/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284545
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,568.00 08/21/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190301445
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,687.50 08/18/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791997
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,016.03 08/15/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284303
Principal investigator 1 Janssen Research & Development, LLC $2,136.00 08/11/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411605
Principal investigator 1 Alexion Pharmaceuticals, Inc. $54,207.50 08/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185549101
Principal investigator 1 ABBVIE INC. $2,272.33 08/05/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202501960
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667124
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 08/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667126
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 08/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667128
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,595.80 08/01/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283577
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,132.40 08/01/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283579
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,200.00 08/01/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223283581
Principal investigator 1 Janssen Research & Development, LLC $6,961.00 07/31/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411558
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 07/31/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411718
Principal investigator 1 UCB SA $50,256.00 07/30/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658650
Principal investigator 1 Amgen Inc. $1,614.43 07/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246642992
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 07/28/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667136
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667138
Principal investigator 1 Boehringer Ingelheim International GmbH $28.04 07/28/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667140
Principal investigator 1 Boehringer Ingelheim International GmbH $10.32 07/28/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667142
Principal investigator 1 Boehringer Ingelheim International GmbH $2.56 07/28/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667144
Principal investigator 1 SANOFI US SERVICES INC. $6,000.00 07/28/2025 Non-covered Recipient Entity
Iris Research And Development LLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128093
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,103.10 07/23/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,334.14 07/18/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282798
Principal investigator 1 Janssen Research & Development, LLC $9,296.00 07/11/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411568
Principal investigator 1 Janssen Research & Development, LLC $5,159.00 07/07/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411615
Principal investigator 1 Janssen Research & Development, LLC $7,750.00 07/07/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411656
Principal investigator 1 Janssen Research & Development, LLC $1,872.00 07/04/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175411669
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 07/02/2025 Non-covered Recipient Entity
Iris Research And Development LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226128083
Principal investigator 1 SANOFI US SERVICES INC. $14,500.00 07/02/2025 Non-covered Recipient Entity
Iris Research And Development LLC
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study No dispute reported 06/30/2026 1226128088
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,555.45 07/02/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282154
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,000.00 07/02/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282182
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 07/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667118
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 07/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667120
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667122
Principal investigator 1 PFIZER INC. $13,660.00 06/28/2025 Non-covered Recipient Entity
IRIS Research and Development LLC
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228851856
Principal investigator 1 Amgen Inc. $18,940.00 06/04/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1246643012
Principal investigator 1 Janssen Research & Development, LLC $8,422.00 06/02/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411553
Principal investigator 1 Janssen Research & Development, LLC $3,657.00 06/02/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411724
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 06/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667112
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667114
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 06/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667116
Principal investigator 1 Mallinckrodt Hospital Products Inc. $80,000.00 05/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
CLINICAL IMPACT OF ACTHAR IN THE PSORIATIC ARTHRITIS PATIENT No dispute reported 06/30/2026 1212110464
Principal investigator 1 Amgen Inc. $609.13 05/27/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS
A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy No dispute reported 06/30/2026 1246642790
Principal investigator 1 Janssen Research & Development, LLC $26,897.00 05/26/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175411704
Principal investigator 1 Eli Lilly and Company $7,475.00 05/23/2025 Non-covered Recipient Entity
IRIS RSRCH AND DEVELOPMENT
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883140
Principal investigator 1 Amgen Inc. $42,134.36 05/21/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246643007
Principal investigator 1 Janssen Research & Development, LLC $12,800.00 05/09/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411595
Principal investigator 1 Janssen Research & Development, LLC $10,140.00 05/08/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411633
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,687.50 05/07/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791993
Principal investigator 1 ABBVIE INC. $2,529.83 05/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202481645
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667106
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 05/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667108
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 05/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667110
Principal investigator 1 Amgen Inc. $56,464.06 04/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
P4 Uncontrolled Gout FORWARD II No dispute reported 06/30/2026 1246643003
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 04/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411644
Principal investigator 1 Janssen Research & Development, LLC $7,494.00 04/11/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411662
Principal investigator 1 Janssen Research & Development, LLC $12,200.00 04/07/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411600
Principal investigator 1 ABBVIE INC. $123.95 04/03/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202468972
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667100
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 04/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667102
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 04/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667104
Principal investigator 1 Janssen Research & Development, LLC $6,614.00 03/31/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411693
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,000.00 03/14/2025 Non-covered Recipient Entity
IRIS RESEARCH DEVELOPMENT LLC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223276737
Principal investigator 1 UCB SA $888.26 03/12/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658414
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,880.60 03/10/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791991
Principal investigator 1 Janssen Research & Development, LLC $14,756.00 03/10/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175411536
Principal investigator 1 ABBVIE INC. $383.75 03/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202458176
Principal investigator 1 UCB SA $181.07 03/06/2025 Non-covered Recipient Entity
INTERGRAL RHEUMATOLOGY & IMMUNOLOGY SPECIALIST
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657650
Principal investigator 1 Janssen Research & Development, LLC $6,200.00 03/03/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411610
Principal investigator 1 Janssen Research & Development, LLC $4,917.00 03/03/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411650
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667094
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 03/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667096
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 03/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667098
Principal investigator 1 Janssen Research & Development, LLC $5,719.00 02/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411640
Principal investigator 1 Novartis Pharmaceuticals Corporation $725.00 02/25/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190309686
Principal investigator 1 Janssen Research & Development, LLC $41,142.00 02/14/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA) No dispute reported 06/30/2026 1175411688
Principal investigator 1 Novartis Pharmaceuticals Corporation $470.67 02/10/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis No dispute reported 06/30/2026 1190301441
Principal investigator 1 ABBVIE INC. $1,764.63 02/05/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202444455
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,750.00 02/05/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190309692
Principal investigator 1 UCB SA $22,976.00 02/05/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659535
Principal investigator 1 Janssen Research & Development, LLC $26,578.00 02/03/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175411710
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 02/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667088
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 02/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667090
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667092
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,880.50 02/01/2025 Non-covered Recipient Entity
Iris Research and Development LLC
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220791989
Principal investigator 1 Janssen Research & Development, LLC $10,296.00 01/31/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175411541
Principal investigator 1 Amgen Inc. $6,247.31 01/30/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS
A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis No dispute reported 06/30/2026 1246642794
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,166.00 01/28/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190309690
Principal investigator 1 Janssen Research & Development, LLC $8,227.00 01/27/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175411682
Principal investigator 1 UCB SA $26,993.00 01/27/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657352
Principal investigator 1 Eli Lilly and Company $10,204.00 01/21/2025 Non-covered Recipient Entity
IRIS RSRCH AND DEVELOPMENT
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883138
Principal investigator 1 Amgen Inc. $664,132.26 01/17/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246643000
Principal investigator 1 Novartis Pharmaceuticals Corporation $45.32 01/15/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190301435
Principal investigator 1 Novartis Pharmaceuticals Corporation $43.50 01/15/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190301443
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,295.90 01/14/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A randomized double blind placebo controlled multicenter phase 2 dose ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjogrens Syndrome No dispute reported 06/30/2026 1190309688
Principal investigator 1 SANOFI US SERVICES INC. $91,350.00 01/13/2025 Non-covered Recipient Entity
Iris Research And Development LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226128071
Principal investigator 1 SANOFI US SERVICES INC. $10,100.00 01/13/2025 Non-covered Recipient Entity
Iris Research And Development LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226128075
Principal investigator 1 SANOFI US SERVICES INC. $26,200.00 01/13/2025 Non-covered Recipient Entity
Iris Research And Development LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With ModeratetoSevere Rheumatoid Arthritis No dispute reported 06/30/2026 1226128079
Principal investigator 1 Eli Lilly and Company $817.77 01/09/2025 Non-covered Recipient Entity
IRIS RSRCH AND DEVELOPMENT
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187885188
Principal investigator 1 Amgen Inc. $91,785.15 01/06/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246642989
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,373.54 01/03/2025 Non-covered Recipient Entity
IRIS RESEARCH AND DEVELOPMENT
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185549103
Principal investigator 1 Boehringer Ingelheim International GmbH $11.58 01/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667082
Principal investigator 1 Boehringer Ingelheim International GmbH $106.19 01/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667084
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Integral Rheumatology And Immunology Specialists-Plantation FL
A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis No dispute reported 06/30/2026 1220667086
Principal investigator 1 Novartis Pharmaceuticals Corporation $457.60 01/01/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190301439
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,583.05 01/01/2025 Non-covered Recipient Entity
INTEGRAL RHEUMATOLOGY AND IMMUNOLOGY SPECIALISTS IRIS .
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190301449